Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients
Satoshi Fujii, Yuta Ibe, Tomoyuki Ishigo, Hirotoshi Inamura, Yusuke Kunimoto, Yoshihiro Fujiya, Koji Kuronuma, Hiromasa Nakata, Masahide Fukudo, Satoshi Takahashi
Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.04.013
Introduction: The antiviral drug favipiravir has been shown to have in vitro antiviral activity against severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2). In this study, we investigated the clinical benefits and initiation of favipiravir treatment in patients with non-severe coronavirus-disease-2019 . Methods: This study was a single-center retrospective cohort study. Receiver operating characteristic curves were drawn to calculate the area under the curve, and the optimal cut-off values for the time to initiate favipiravir treatment were calculated to predict defervescence within seven days. Univariate and multivariate Cox regression analyses were performed to identify potential influencing factors of defervescence. This was defined as a body temperature of less than 37 C for at least 2 days. Results: Data from 41 patients were used for the efficacy assessment. The days from the onset of fever to defervescence showed a positive correlation with the duration from the onset of fever to initiation of favipiravir treatment (r ¼ 0.548, P < 0.001). The optimal cut-off value was the administration of favipiravir on day 4. Patients were assigned to two groups based on the optimal cut-off value from onset to initiation of favipiravir treatment: early treatment group (within 4-days) and late treatment group (more than 4-days). In the multivariate analysis, when adjusted for age, sex, and days from onset to initiation of favipiravir treatment, the significant factors were male sex and days of initiation of the favipiravir treatment. Conclusions: We recommend that if favipiravir is to be used for treatment, it should be initiated as early as possible.
References
Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering,
doi:10.1016/j.eng.2020.03.007Doi, Hibino, Hase, Yamamoto, Kasamatsu et al., A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19, Antimicrob Agents Chemother,
doi:10.1128/AAC.01897-20Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci,
doi:10.2183/pjab.93.027Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med,
doi:10.1056/NEJMoa2002032Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a Phase II/III multicenter randomized clinical trial, Clin Infect Dis,
doi:10.1093/cid/ciaa1176Kaptein, Jacobs, Langendries, Seldeslachts, Horst et al., Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2014441117Nakamura, Ide, Saito, Kinoshita, Kutsuna et al., COVID-19 can suddenly become severe: a case series from Tokyo, Japan, Glob Health Med,
doi:10.35772/ghm.2020.01054Peckham, De Gruijter, Raine, Radziszewska, Ciurtin et al., Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission, Nat Commun,
doi:10.1038/s41467-020-19741-6Pilkington, Pepperrell, Hill, A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic?, J Virus Erad,
doi:10.1016/S2055-6640(20)30016-9Tani, Fukuma, Fukushi, Taniguchi, Yoshikawa et al., Efficacy of T-705 (favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus, mSphere,
doi:10.1128/mSphere.00061-15Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, Phase 3 clinical trial, Int J Infect Dis,
doi:10.1016/j.ijid.2020.11.142Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, J Am Med Assoc,
doi:10.1001/jama.2020.1585Wiersinga, Rhodes, Cheng, Peacock, Prescott, Pathophysiology, transmission, diagnosis, and treatment of coronavirus Disease 2019 (COVID-19): a review, J Am Med Assoc,
doi:10.1001/jama.2020.12839Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention, J Am Med Assoc,
doi:10.1001/jama.2020.2648Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)30566-3Zhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med,
doi:10.1056/NEJMoa2001017
